RT Journal Article
SR Electronic
T1 Characterising SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.06.21249368
DO 10.1101/2021.01.06.21249368
A1 James A Watson
A1 Stephen Kissler
A1 Nicholas PJ Day
A1 Yonatan Grad
A1 Nicholas J White
YR 2022
UL http://medrxiv.org/content/early/2022/02/11/2021.01.06.21249368.abstract
AB A consensus methodology for pharmacometric assessment of candidate SARS-CoV-2 antiviral drugs would be useful for comparing trial results and improving trial design. The time to viral clearance, assessed by serial qPCR of nasopharyngeal swab samples, has been the most widely reported measure of virological response in clinical trials, but it has not been compared formally with other metrics, notably model-based estimates of the rate of viral clearance. We analysed prospectively gathered viral clearance profiles from 280 infection episodes in vaccinated and unvaccinated individuals. We fitted different phenomenological pharmacodynamic models (single exponential decay, bi-exponential, penalised splines) and found that the clearance rate, estimated from a mixed effects single exponential decay model, is a robust pharmacodynamic summary of viral clearance. The rate of viral clearance, estimated from viral densities during the first week following peak viral load, provides increased statistical power (reduced type 2 error) compared with time to clearance. We recommend that pharmacometric antiviral assessments should be conducted in early illness with serial qPCR samples taken over one week.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWellcome Trust Grant 093956/Z/10/CAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable: we used de-identified open access data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are available on the github repositories linked to this manuscript. https://github.com/gradlab/CtTrajectories https://github.com/jwatowatson/phase2sims